Heme/Onc - Week 1 Review - Part 2 Flashcards
Four Major Chemotherapy Drug Classes
1) Alkylators
2) ANtimetabolities
3) DNA Repair Inhibitor
4) Anti-Tubulins
Cancers with a Chemotherapy as a Possible Cure (3)
1) Hodgkin
2) NHL
3) Testicular
Cancers with Chemotherapy Survival Benefit (6)
1) Breast
2) Ovarian
3) Endometrial
4) Cervical
5) Small Cell Lung
6) Colorectal
Alkylating Agents - Major Mechanism + Major Toxicities (4)
Mechanism - Trigger bifunctional moieties –> cause double strand breaks
Toxicity - GI Tract + Bone Marrow + Vesicant (infiltration) + Carcinogenic (Increased risk for of AML later in life)
CHOP Therapy for NHL and CLL
Cyclophosphamide (Alkylator) + Hydroxydaunorubicin (Doxorubicin) + Nocovorin (Vincristine - Microtubule Inhibitor) + Prednisone
Generics = CDVP
Capecitabine - Major Function + Toxicity
Function - Prodrug - Antimetabolite
Causes Foot and Hand Syndrome
Leucovorin - Mechanism + Toxicity
Mech - Methotrexate Rescue Drug
No Tox (Tricky)
6-MP - Key Toxicity
6-MP Deactivated by Xanthine Oxidase - XO is knocked out by allopurinol - must be careful for co-administration
Topoisomerase Inhibitors - Class + Name (3)
Topotecan - Top-1 Inhibitor = Single Strand DNA
Etoposide - Top-2 Inhibitor = Double Strand DNA
Vinblastine vs. Vincristine - Major Side Effect
Vinblastine - Vesicant (Infiltration)
Vincristine - Neurotoxicity
Lead Time Interval + Bias
Interval - Time from when you would detect disease on screening vs. when the patient would naturally present with s/sx
Bias - Because you see disease early patients who are screened may “live longer” but you may not be slowing the disease, you’re just seeing the course longer
Length Bias
Diseases caught on screening are more likely to be slower and less aggressive (rapid/aggressive will show symptoms fast)
Prevalence Impact on Screening
High Prevalence increases PPV of a test (more likely to get it right) - Over time screening reduces the prevalence of disease which reduces the effectiveness of the test
PSA Testing - Screening Basics
10/100 People Screened with PSA will be Postive
Of Those 10 who are positive 3 will have disease (30%)
Of The 90 who are negative 1 will have the disease (1/90)
Imantinib - Key Mechanism + Resistance Site
Mechanism - Blocks BCR-Abl fro t(9:22) in CML
Resistance Pathway - Change in the binding cleft of BCR-Abl
Trastuzumab - Mechanism + Key Toxicity
Alternative Name - (Herceptin)
Mechanism - HER2 Signaling
Toxicity - Cardiotoxic (with Doxorubicin)
Chronology of Hematopoesis Location During Development - 5 Sites Prior to Birth
1) Yolk Sac
2) Placenta
3-4) Spleen + Fetal Liver
5) Bone Marrow
Hematopoeisis Over A Life Time - Locations (After Birth)
High In tibia and femur at both - degenerate and central locations take over
Age 75 - Vertebrae still 75% cellular
Age 20 - Femur only 25% cellular
Embryological Origin of Bone Marrow
Mesoderm
HSC Niche - 5 Major Factors
1) Osteoblast Notch Pathway
2-4) Endothelial Cells - Kit + CXCL12 and 4
5) Thrombopoetin (Platlet stimulating factor)
Major HSC Markers (3)
1) CD34+ - N-Terminus binds ICAM and holds in the Niche
2) Thy1+
3) CD33(-)